{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T18:59:54Z","timestamp":1790794794357,"version":"4.1.0"},"reference-count":50,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2020,4,16]],"date-time":"2020-04-16T00:00:00Z","timestamp":1586995200000},"content-version":"unspecified","delay-in-days":15,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Intramural Research Program, National Cancer Institute, NIH","award":["ZIA BC 010944: Strategies for Cancer Immunotherapy"],"award-info":[{"award-number":["ZIA BC 010944: Strategies for Cancer Immunotherapy"]}]},{"name":"Cooperative Research and Development Agreement between the National Cancer Institute and ImmunityBio, Inc.","award":["CRADA #03063"],"award-info":[{"award-number":["CRADA #03063"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2020,3,11]]},"published-print":{"date-parts":[[2020,4]]},"abstract":"<jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Anti(\u03b1)-programmed cell death-1 (PD-1)\/programmed death-ligand 1 (PD-L1) monotherapy fails to provide durable clinical benefit for most patients with carcinoma. Recent studies suggested that strategies to reduce immunosuppressive cells, promote systemic T-cell responses and lymphocyte trafficking to the tumor microenvironment (TME) may improve efficacy. N-809 is a first-in-class bifunctional agent comprising the interleukin (IL)-15 superagonist N-803 fused to two \u03b1PD-L1 domains. Thus, N-809 can potentially stimulate effector immune cells through IL-15 and block immunosuppressive PD-L1. Here, we examined the antitumor efficacy and immunomodulatory effects of N-809 versus N-803+\u03b1PD-L1 combination.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>The ability of N-809 to block PD-L1 and induce IL-15-dependent immune effects was examined in vitro and in vivo. Antitumor efficacy of N-809 or N-803+\u03b1PD-L1 was evaluated in two murine carcinoma models and an extensive analysis of immune correlates was performed in the tumor and tumor-draining lymph node (dLN).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>We demonstrate that N-809 blocks PD-L1 and induces IL-15-dependent immune effects. N-809 was well-tolerated and reduced 4T1 lung metastasis, decreased MC38 tumor burden and increased survival versus N-803+\u03b1PD-L1. Compared with N-803+\u03b1PD-L1, N-809 enhanced natural killer (NK) and CD8<jats:sup>+<\/jats:sup> T-cell activation and function in the dLN and TME, relating to increased gene expression associated with interferon and cytokine signaling, lymphoid compartment, costimulation and cytotoxicity. The higher number of TME CD8<jats:sup>+<\/jats:sup> T cells was attributed to enhanced infiltration, not in situ expansion. Increased TME NK and CD8<jats:sup>+<\/jats:sup> T-cell numbers correlated with augmented chemokine ligands and receptors. Moreover, in contrast to N-803+\u03b1PD-L1, N-809 reduced immunosuppressive regulatory T cells (T<jats:sub>reg<\/jats:sub>), monocytic myeloid-derived suppressor cells (M-MDSC) and M2-like macrophages in the TME.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Our results suggest that N-809 functions by a novel immune mechanism to promote antitumor efficacy. Foremost, N-809 enhances intratumoral lymphocyte numbers by increasing trafficking via altered chemokine levels in the TME and chemokine receptor expression on CD8<jats:sup>+<\/jats:sup> T cells and NK cells. In addition, N-809 reduces immunosuppressive and pro-tumorigenic immune cells in the TME, including T<jats:sub>reg<\/jats:sub>, M2-like macrophages and M-MDSC. Overall, these novel effects of N-809 promote an inflamed TME, leading to lower tumor burden and increased survival. These results provide mechanistic insight and rationale supporting the potential clinical study of N-809 in patients with carcinoma.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/jitc-2019-000493","type":"journal-article","created":{"date-parts":[[2020,4,17]],"date-time":"2020-04-17T07:06:59Z","timestamp":1587107219000},"page":"e000493","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":49,"title":["Functional and mechanistic advantage of the use of a bifunctional anti-PD-L1\/IL-15 superagonist"],"prefix":"10.1136","volume":"8","author":[{"given":"Karin M","family":"Knudson","sequence":"first","affiliation":[{"name":"Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristin C","family":"Hicks","sequence":"additional","affiliation":[{"name":"Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yohei","family":"Ozawa","sequence":"additional","affiliation":[{"name":"Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7932-4072","authenticated-orcid":false,"given":"Jeffrey","family":"Schlom","sequence":"additional","affiliation":[{"name":"Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2392-8122","authenticated-orcid":false,"given":"Sofia R","family":"Gameiro","sequence":"additional","affiliation":[{"name":"Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2020,4,16]]},"reference":[{"key":"2025100310312334000_8.1.e000493.1","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2015.209"},{"key":"2025100310312334000_8.1.e000493.2","doi-asserted-by":"crossref","unstructured":"Fransen MF , Schoonderwoerd M , Knopf P , et al . Tumor-draining lymph nodes are pivotal in PD-1\/PD-L1 checkpoint therapy. JCI Insight 2018;3. doi:doi:10.1172\/jci.insight.124507. [Epub ahead of print: 06 Dec 2018].","DOI":"10.1172\/jci.insight.124507"},{"key":"2025100310312334000_8.1.e000493.3","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.cell.2016.12.022","article-title":"Systemic immunity is required for effective cancer immunotherapy","volume":"168","author":"Spitzer","year":"2017","journal-title":"Cell"},{"key":"2025100310312334000_8.1.e000493.4","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-18-3208"},{"key":"2025100310312334000_8.1.e000493.5","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-019-0522-3"},{"key":"2025100310312334000_8.1.e000493.6","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aad7118","article-title":"Pd-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: mechanisms, response biomarkers, and combinations","volume":"8","author":"Zou","year":"2016","journal-title":"Sci Transl Med"},{"key":"2025100310312334000_8.1.e000493.7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1503093"},{"key":"2025100310312334000_8.1.e000493.8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1613493"},{"key":"2025100310312334000_8.1.e000493.9","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1200\/JCO.2016.71.6795","article-title":"Avelumab, an anti-programmed death-ligand 1 antibody, in patients with refractory metastatic urothelial carcinoma: results from a multicenter, phase Ib study","volume":"35","author":"Apolo","year":"2017","journal-title":"J Clin Oncol"},{"key":"2025100310312334000_8.1.e000493.10","doi-asserted-by":"crossref","unstructured":"Waldmann TA . Cytokines in cancer immunotherapy. Cold Spring Harb Perspect Biol 2018;10. doi:doi:10.1101\/cshperspect.a028472. [Epub ahead of print: 03 Dec 2018].","DOI":"10.1101\/cshperspect.a028472"},{"key":"2025100310312334000_8.1.e000493.11","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.57.3329"},{"key":"2025100310312334000_8.1.e000493.12","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-17-2451"},{"key":"2025100310312334000_8.1.e000493.13","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-15-0093-T"},{"key":"2025100310312334000_8.1.e000493.14","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-0945"},{"key":"2025100310312334000_8.1.e000493.15","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1016\/S1470-2045(18)30148-7","article-title":"ALT-803, an IL-15 superagonist, in combination with nivolumab in patients with metastatic non-small cell lung cancer: a non-randomised, open-label, phase 1B trial","volume":"19","author":"Wrangle","year":"2018","journal-title":"Lancet Oncol"},{"key":"2025100310312334000_8.1.e000493.16","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-019-0551-y"},{"key":"2025100310312334000_8.1.e000493.17","doi-asserted-by":"publisher","DOI":"10.1038\/icb.2014.93"},{"key":"2025100310312334000_8.1.e000493.18","doi-asserted-by":"publisher","DOI":"10.1002\/jcb.26005"},{"key":"2025100310312334000_8.1.e000493.19","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2018.00315","article-title":"Immuno-Oncology: emerging targets and combination therapies","volume":"8","author":"Marshall","year":"2018","journal-title":"Front Oncol"},{"key":"2025100310312334000_8.1.e000493.20","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aan5488","article-title":"Enhanced preclinical antitumor activity of M7824, a bifunctional fusion protein simultaneously targeting PD-L1 and TGF-\u03b2","volume":"10","author":"Lan","year":"2018","journal-title":"Sci Transl Med"},{"key":"2025100310312334000_8.1.e000493.21","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2018.1532764","article-title":"The multi-functionality of N-809, a novel fusion protein encompassing anti-PD-L1 and the IL-15 superagonist fusion complex","volume":"8","author":"Jochems","year":"2019","journal-title":"Oncoimmunology"},{"key":"2025100310312334000_8.1.e000493.22","first-page":"499","article-title":"In vitro and in vivo antitumor properties of a T-cell clone generated from murine tumor-infiltrating lymphocytes","volume":"9","author":"Fox","year":"1990","journal-title":"J Biol Response Mod"},{"key":"2025100310312334000_8.1.e000493.23","first-page":"Unit 20.2","article-title":"Mouse 4T1 breast tumor model","volume":"Chapter 20","author":"Pulaski","year":"2001","journal-title":"Curr Protoc Immunol"},{"key":"2025100310312334000_8.1.e000493.24","doi-asserted-by":"crossref","first-page":"16130","DOI":"10.18632\/oncotarget.7470","article-title":"Il-15 superagonist\/IL-15R\u03b1Sushi-Fc fusion complex (IL-15SA\/IL-15R\u03b1Su-Fc; ALT-803) markedly enhances specific subpopulations of NK and memory CD8+ T cells, and mediates potent anti-tumor activity against murine breast and colon carcinomas","volume":"7","author":"Kim","year":"2016","journal-title":"Oncotarget"},{"key":"2025100310312334000_8.1.e000493.25","doi-asserted-by":"publisher","DOI":"10.1007\/s00018-012-0968-7"},{"key":"2025100310312334000_8.1.e000493.26","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-12-823757"},{"key":"2025100310312334000_8.1.e000493.27","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.180.9.5771"},{"key":"2025100310312334000_8.1.e000493.28","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2005.05.002"},{"key":"2025100310312334000_8.1.e000493.29","doi-asserted-by":"crossref","first-page":"2265","DOI":"10.1016\/j.jaci.2017.11.022","article-title":"S1Pr5 is essential for human natural killer cell migration toward sphingosine-1 phosphate","volume":"141","author":"Drouillard","year":"2018","journal-title":"J Allergy Clin Immunol"},{"key":"2025100310312334000_8.1.e000493.30","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20090525"},{"key":"2025100310312334000_8.1.e000493.31","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms8458","article-title":"Non-Redundant requirement for CXCR3 signalling during tumoricidal T-cell trafficking across tumour vascular checkpoints","volume":"6","author":"Mikucki","year":"2015","journal-title":"Nat Commun"},{"key":"2025100310312334000_8.1.e000493.32","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-14-2458"},{"key":"2025100310312334000_8.1.e000493.33","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-065X.2007.00563.x"},{"key":"2025100310312334000_8.1.e000493.34","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M116.733600"},{"key":"2025100310312334000_8.1.e000493.35","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.28059"},{"key":"2025100310312334000_8.1.e000493.36","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-18-1204"},{"key":"2025100310312334000_8.1.e000493.37","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1001\/jamaoncol.2019.0836","article-title":"Assessment of subcutaneous vs intravenous administration of anti-PD-1 antibody PF-06801591 in patients with advanced solid tumors: a phase 1 dose-escalation trial","volume":"5","author":"Johnson","year":"2019","journal-title":"JAMA Oncol"},{"key":"2025100310312334000_8.1.e000493.38","doi-asserted-by":"crossref","first-page":"e272","DOI":"10.1016\/S2352-3026(17)30078-9","article-title":"Efficacy and safety of subcutaneous rituximab versus intravenous rituximab for first-line treatment of follicular lymphoma (SABRINA): a randomised, open-label, phase 3 trial","volume":"4","author":"Davies","year":"2017","journal-title":"Lancet Haematol"},{"key":"2025100310312334000_8.1.e000493.39","doi-asserted-by":"crossref","first-page":"49008","DOI":"10.18632\/oncotarget.10264","article-title":"Identification of IFN-\u03b3-producing T cells as the main mediators of the side effects associated to mouse interleukin-15 sustained exposure","volume":"7","author":"Di Scala","year":"2016","journal-title":"Oncotarget"},{"key":"2025100310312334000_8.1.e000493.40","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1500300"},{"key":"2025100310312334000_8.1.e000493.41","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-17-0495"},{"key":"2025100310312334000_8.1.e000493.42","doi-asserted-by":"publisher","DOI":"10.1016\/j.coi.2016.03.006"},{"key":"2025100310312334000_8.1.e000493.43","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-03-275438"},{"key":"2025100310312334000_8.1.e000493.44","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.29686"},{"key":"2025100310312334000_8.1.e000493.45","doi-asserted-by":"publisher","DOI":"10.1038\/ni.3868"},{"key":"2025100310312334000_8.1.e000493.46","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-018-36403-2","article-title":"PD-1\/PD-L1 Pathway Modulates Macrophage Susceptibility to Mycobacterium tuberculosis Specific CD8+ T cell Induced Death","volume":"9","author":"Suarez","year":"2019","journal-title":"Sci Rep"},{"key":"2025100310312334000_8.1.e000493.47","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1007654108"},{"key":"2025100310312334000_8.1.e000493.48","doi-asserted-by":"crossref","first-page":"6125","DOI":"10.2147\/CMAR.S199832","article-title":"M2 macrophage infiltration into tumor islets leads to poor prognosis in non-small-cell lung cancer","volume":"11","author":"Cao","year":"2019","journal-title":"Cancer Manag Res"},{"key":"2025100310312334000_8.1.e000493.49","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1007\/s00005-017-0463-9","article-title":"Tumor-Associated macrophages and regulatory T cells infiltration and the clinical outcome in colorectal cancer","volume":"65","author":"Waniczek","year":"2017","journal-title":"Arch Immunol Ther Exp"},{"key":"2025100310312334000_8.1.e000493.50","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.imlet.2017.10.001","article-title":"Expression of checkpoint molecules on myeloid-derived suppressor cells","volume":"192","author":"Ballbach","year":"2017","journal-title":"Immunol Lett"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2019-000493","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T17:31:30Z","timestamp":1759512690000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2019-000493"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4]]},"references-count":50,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,4,16]]},"published-print":{"date-parts":[[2020,4]]}},"alternative-id":["10.1136\/jitc-2019-000493"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2019-000493","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4]]}}}